Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR)

A 43‐year‐old female with multiple sclerosis developed urethral melanoma. The only potential risk factor was treatment with natalizumab, a humanized monoclonal antibody against α4 integrins. To investigate the risk‐exposure relationship, we reviewed this case, all other published cases, and cases of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sabol, Rachel A., Noxon, Virginia, Sartor, Oliver, Berger, Joseph R., Qureshi, Zaina, Raisch, Dennis W., Norris, LeAnn B., Yarnold, Paul R., Georgantopoulos, Peter, Hrushesky, William J., Bobolts, Laura, Ray, Paul, Lebby, Akida, Kane, Robert C., Bennett, Charles L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504343/
https://www.ncbi.nlm.nih.gov/pubmed/28635055
http://dx.doi.org/10.1002/cam4.1098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504343/
https://www.ncbi.nlm.nih.gov/pubmed/28635055
http://dx.doi.org/10.1002/cam4.1098

Ejemplares similares